BlackRock’s Altimmune ALT Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $39.4M | Buy |
12,795,277
+3,090,979
| +32% | +$13.1M | ﹤0.01% | 2669 |
|
|
2025
Q4 | $35M | Buy |
9,704,298
+3,331,039
| +52% | +$14.5M | ﹤0.01% | 2747 |
|
|
2025
Q3 | $24M | Buy |
6,373,259
+699
| +0% | +$2.7K | ﹤0.01% | 2980 |
|
|
2025
Q2 | $24.7M | Buy |
6,372,560
+237,330
| +4% | +$1.28M | ﹤0.01% | 2889 |
|
|
2025
Q1 | $30.7M | Sell |
6,135,230
-24,075
| -0.4% | -$153K | ﹤0.01% | 2679 |
|
|
2024
Q4 | $44.4M | Buy |
6,159,305
+693,211
| +13% | +$5.3M | ﹤0.01% | 2526 |
|
|
2024
Q3 | $33.6M | Buy |
5,466,094
+145,005
| +3% | +$982K | ﹤0.01% | 2710 |
|
|
2024
Q2 | $35.4M | Buy |
5,321,089
+1,278,863
| +32% | +$9.44M | ﹤0.01% | 2624 |
|
|
2024
Q1 | $41.1M | Sell |
4,042,226
-2,481
| -0.1% | -$25.2K | ﹤0.01% | 2555 |
|
|
2023
Q4 | $45.5M | Buy |
4,044,707
+257,791
| +7% | +$1.08M | ﹤0.01% | 2534 |
|
|
2023
Q3 | $9.85M | Buy |
3,786,916
+122,642
| +3% | +$352K | ﹤0.01% | 3342 |
|
|
2023
Q2 | $12.9M | Buy |
3,664,274
+2,270,219
| +163% | +$10.2M | ﹤0.01% | 3294 |
|
|
2023
Q1 | $5.88M | Buy |
1,394,055
+40,022
| +3% | +$475K | ﹤0.01% | 3562 |
|
|
2022
Q4 | $22.3M | Buy |
1,354,033
+134,733
| +11% | +$1.51M | ﹤0.01% | 2972 |
|
|
2022
Q3 | $15.6M | Buy |
1,219,300
+257,116
| +27% | +$3.8M | ﹤0.01% | 3179 |
|
|
2022
Q2 | $11.3M | Sell |
962,184
-1,974,140
| -67% | -$12.2M | ﹤0.01% | 3440 |
|
|
2022
Q1 | $17.9M | Sell |
2,936,324
-19,943
| -0.7% | -$147K | ﹤0.01% | 3240 |
|
|
2021
Q4 | $27.1M | Buy |
2,956,267
+14,477
| +0.5% | +$154K | ﹤0.01% | 3089 |
|
|
2021
Q3 | $33.3M | Buy |
2,941,790
+384,548
| +15% | +$4.68M | ﹤0.01% | 2927 |
|
|
2021
Q2 | $25.2M | Buy |
2,557,242
+1,499,055
| +142% | +$20.5M | ﹤0.01% | 3157 |
|
|
2021
Q1 | $15M | Buy |
1,058,187
+65,511
| +7% | +$1.06M | ﹤0.01% | 3344 |
|
|
2020
Q4 | $11.2M | Buy |
992,676
+495,943
| +100% | +$5.84M | ﹤0.01% | 3301 |
|
|
2020
Q3 | $6.56M | Sell |
496,733
-84,547
| -15% | -$1.69M | ﹤0.01% | 3457 |
|
|
2020
Q2 | $6.22M | Buy |
581,280
+545,063
| +1,505% | +$2.99M | ﹤0.01% | 3437 |
|
|
2020
Q1 | $116K | Buy |
36,217
+2,025
| +6% | +$4.66K | ﹤0.01% | 4326 |
|
|
2019
Q4 | $64K | Sell |
34,192
-354
| -1% | -$654 | ﹤0.01% | 4505 |
|
|
2019
Q3 | $67K | Sell |
34,546
-1,949
| -5% | -$4.32K | ﹤0.01% | 4497 |
|
|
2019
Q2 | $87K | Buy |
36,495
+36,308
| +19,416% | +$97.1K | ﹤0.01% | 4490 |
|
|
2019
Q1 | $0 | Buy |
187
+1
| +0.5% | +$3 | ﹤0.01% | 4920 |
|
|
2018
Q4 | $0 | Buy |
186
+3
| +2% | +$11 | ﹤0.01% | 4946 |
|
|
2018
Q3 | $1K | Buy |
183
+3
| +2% | +$33 | ﹤0.01% | 4916 |
|
|
2018
Q2 | $3K | Sell |
180
-980
| -84% | -$19.3K | ﹤0.01% | 4859 |
|
|
2018
Q1 | $40K | Sell |
1,160
-68
| -6% | -$3.41K | ﹤0.01% | 4465 |
|
|
2017
Q4 | $73K | Buy |
1,228
+48
| +4% | +$3.07K | ﹤0.01% | 4380 |
|
|
2017
Q3 | $82K | Sell |
1,180
-42
| -3% | -$3.13K | ﹤0.01% | 4398 |
|
|
2017
Q2 | $117K | Sell |
1,222
-7,991
| -87% | -$1.33M | ﹤0.01% | 4371 |
|
|
2017
Q1 | $2.24M | Buy |
9,213
+9,202
| +83,655% | +$4.92M | ﹤0.01% | 3620 |
|
|
2016
Q4 | $11K | Hold |
11
| – | – | ﹤0.01% | 3367 |
|
|
2016
Q3 | $10K | Buy |
11
+4
| +57% | +$3.14K | ﹤0.01% | 3395 |
|
|
2016
Q2 | $5K | Buy |
+7
| New | +$4.79K | ﹤0.01% | 3508 |
|
Other funds holding ALT
VCM
VPM
N
BlackRock's ALT Position: Q1 2026 in Review
BlackRock increased its Altimmune (ALT) stake by 32% in Q1 2026, buying an estimated $13.1M and bringing the position to 12,795,277 shares worth $39.4M. The position accounts for ﹤0.01% of the portfolio, ranked #2669.
BlackRock first reported a position in ALT in Q2 2016 and has held it in 40 quarters since. The position peaked at $45.5M in Q4 2023. 173 funds tracked by Wall St. Rank hold ALT as of Q1 2026.
- BlackRock held 12,795,277 shares of Altimmune worth $39.4M as of Q1 2026.
- BlackRock bought 3,090,979 Altimmune shares in Q1 2026, an estimated $13.1M.
- Altimmune made up ﹤0.01% of BlackRock's portfolio in Q1 2026, its #2669 holding.
- BlackRock first reported a position in Altimmune in Q2 2016 and has held it in 40 quarters since.
- BlackRock's Altimmune position peaked at $45.5M in Q4 2023.
- 173 funds tracked by Wall St. Rank held Altimmune as of Q1 2026.
Based on BlackRock's 13F filing for Q1 2026, filed 13 May 2026.